Wolverine Legal Status, FDA 503A Category, and Compounding Access

Where access stands — and where it may be heading

The momentum is real: access to these peptides is under active FDA review, and it may expand in 2026. The U.S. Food and Drug Administration has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026 to discuss BPC-157 and TB-500 — among other peptides — as substances "being considered for inclusion on the 503A Bulks List" ^[13]. That is a concrete, dated step in an evaluation that is genuinely live. It is not a decision, not a reclassification, and not a guaranteed outcome — a PCAC discussion is advisory, and inclusion on a final bulks list is decided later by FDA rulemaking ^[12].

With that direction set, here is the present-tense fact the marketing tends to skip. As of now, both of the Wolverine blend's constituents sit in FDA's 503A "Category 2" — bulk drug substances the FDA identified as possibly presenting significant safety risks — effective with the September 29, 2023 update to its nominated-substances list ^[11]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, which means routine 503A compounding-pharmacy access to these ingredients is currently restricted while that status stands ^[12]. The forward motion is the July 2026 review; the floor underneath it is Category 2 today.

What is the FDA 503A status of the blend?

What is the FDA 503A status of the blend?

Both constituents are in FDA 503A Category 2. The FDA lists BPC-157 (as "BPC-157 (free base)" and "BPC-157 acetate") and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" among bulk drug substances that may present significant safety risks, effective with the September 29, 2023 list update, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization ^[11]. Section 503A covers patient-specific compounding by state-licensed pharmacies and physicians; a bulk substance may be used only if it has a USP/NF monograph, is a component of an approved drug, or is on the 503A bulks list ^[12]. There is no separate FDA status for the blend as an entity — the status is read per constituent, and both read Category 2.

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither BPC-157 nor TB-500 is FDA-approved for human use, and both are placed in FDA's 503A Category 2 of bulk substances flagged for significant safety risks pending review ^[11]. Both constituents are also prohibited by the World Anti-Doping Agency. So the answer is the same in both corners: not approved, and banned in sport.

Both fighters are on the same scheduled review

There is no component carve-out in this matchup. BPC-157 and TB-500 are both currently Category 2, and both are on the one scheduled review. The FDA's public calendar lists BPC-157 and TB-500 — alongside other peptides — as bulk drug substances "being considered for inclusion on the 503A Bulks List" to be discussed at the July 23-24, 2026 PCAC meeting ^[13].

That single agenda item is the entire forward-looking story, and it should be read exactly as the FDA frames it: a scheduled discussion of substances under evaluation, not a listing decision and not a change in current status ^[13]. The blue corner (BPC-157) and the red corner (TB-500) go into that review together. Whatever the committee discusses, the present-tense status of both remains Category 2 until and unless the FDA takes a final action ^[12]. This page does not assert any future outcome, date, or reclassification as settled — because none is.

How legal compounded peptide access works

Setting the blend aside, it helps to know how legal compounded access works in general for this class of substance. A legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[12]. Telehealth can serve as the front-end channel for that evaluation, but it does not change which substances are eligible to be compounded and does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[12].

From there, the prescription is dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office and batch volumes, sourced from an FDA-registered 503B outsourcing facility ^[12]. The decisive caveat: a compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list ^[12]. Ingredients the FDA has flagged for significant safety risks, which currently includes both of this blend's constituents, are not eligible for routine 503A compounding while that status stands ^[11][12].

This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. It names no pharmacy, clinic, telehealth provider, or vendor, gives no dosing or administration instructions, and describes no way to obtain a restricted substance outside the lawful framework.

Can you get BPC-157 from a compounding pharmacy?

Can you get BPC-157 from a compounding pharmacy?

Routine 503A compounding-pharmacy access to BPC-157 is currently restricted. The FDA placed BPC-157 in 503A Category 2 — bulk substances flagged for significant safety risks — effective September 29, 2023, and Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1 ^[11][12]. A compounder may use a bulk ingredient only if it is eligible under the 503A rules, and BPC-157's current status keeps it outside routine 503A compounding while that status stands ^[12]. Lawful compounded access generally requires a licensed-prescriber evaluation, a valid patient-specific prescription, and an eligible ingredient — the last condition is the one currently in question.

Is Wolverine legal?

The Wolverine blend is a pairing of two substances neither of which is FDA-approved for human use, and both of which are in FDA's 503A Category 2 of bulk substances flagged for significant safety risks ^[11]. There is no approved blend product, both constituents are WADA-prohibited, and routine compounding access to the ingredients is currently restricted ^[12]. The status is under active FDA review, with the July 2026 PCAC meeting scheduled — but as a discussion, not a decision ^[13]. General information, not legal advice.

What are the side effects of BPC-157 and TB-500?

Long-term human safety is unknown for both constituents, and the FDA's Category 2 placement cites potential immunogenicity for certain routes and characterization complexity ^[11]. The main literature-flagged concern is a theoretical tumor and angiogenesis signal tied to Thymosin Beta-4 ^[4]. Combining two unapproved peptides compounds the uncertainty; no controlled blend safety data exist ^[8].

Does TB-500 cause cancer or promote tumor growth?

Thymosin Beta-4 is implicated in tumor metastasis and tumor angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression ^[4]. This is a flagged safety consideration, not a demonstrated human effect of the blend; no controlled human data address the combination ^[8].